Total Revenue

N/A (Q4 standalone figure: $338.569 million)

Q4 revenue of $338.569 million indicates robust topline performance, likely building on prior period organic growth and post-IPO expansion; however, no direct Q3 comparison is provided to compute a percentage change. "

Cost of Goods Sold

N/A (Q4 standalone figure: $271.465 million)

COGS of $271.465 million produces a gross profit of $67.104 million, reflecting ongoing cost pressures and production expenses consistent with historical operational challenges. "

Operating Income

N/A (Q4 standalone figure: $16.755 million)

Operating income at $16.755 million shows moderated margins that may be impacted by rising operating expenses despite revenue growth, echoing challenges observed in previous periods. "

Net Income

N/A (Q4 standalone figure: $11.841 million)

Net income of $11.841 million reflects a marginal profitability profile that follows historical trends where rising expenses partially offset revenue gains. "

Operating Cash Flow

N/A (Q4 standalone figure: $22.337 million generated)

Operating cash flow of $22.337 million indicates strong core operations; this positive cash generation is a carry‐over strength from previous periods even as other liquidity metrics experienced volatility. "

Cash & Cash Equivalents

Approximately –87% (decrease from $37.221M to $4.660M)

The steep decline in cash (from $37.221 million in Q3 2024 to $4.660 million in Q4 2024) suggests significant outflows—potentially from financing activities (such as distributions or debt repayments) or reinvestment decisions—despite solid operating cash flows, marking a strategic shift from earlier periods. " "

Accounts Receivable

Approximately +7% (increase from $90.943M to $97.153M)

The 7% rise in accounts receivable is likely driven by continued revenue growth and possibly more lenient credit terms amid expansion efforts, including the recent integration effects from the Heartland Pharmacy acquisition that also contributed to previous period increases. " "

Inventories

Approximately –10% (decline from $45.216M to $40.550M)

The 10% decline in inventories may indicate improved inventory management and tighter alignment with current demand, potentially reflecting integration synergies and cost control measures implemented following prior period adjustments and acquisitions. " "